Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advancing the Effective Delivery of Cannabinoids

Experiments with next-generation delivery systems appear certain to lead to better cannabis-based products. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has recently seen spectacular improvements in the effectiveness of cannabinoids thanks to its proprietary chemical delivery treatment. GW Pharmaceuticals Plc (NASDAQ: GWPH) (OTC: GWPRF), which has won widespread praise for its innovative medical work, has seen good trial results for a new treatment for seizures.  Tilray Inc. (NASDAQ: TLRY) is supporting studies into the uses of cannabinoids to treat behavioral problems and HIV. MariMed Inc. (OTCQB: MRMD) has set up a subsidiary focused on CBD, currently the highest-profile cannabinoid product. Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) has established a new research lab to develop devices for CBD consumption.